AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29313415
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) plus psychostimulant
Trial: 31340800
Drug: Calorie Counting
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calorie Counting (CC)
Trial: 16443788
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at rest
Trial: 10331397
Drug: Insulin effects
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin effects on glucose uptake and alanine transport
Trial: 10331397
Drug: Insulin effects
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin effects on phenylalanine, leucine, and lysine transport
Trial: 8942881
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (fortified tobramycin 1.3%-cefazolin 5.0%)
Trial: 9810943
Drug: Subcutaneous apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous apomorphine
Trial: 7079905
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron plus folic acid
Trial: 7079905
Drug: Intravenous iron‐dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron‐dextran (Imferon; Fisons)
Trial: 22237735
Drug: Carperitide (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carperitide (0.02 g/kg/min, initiated at the start of surgery and continued for ≥5 days)
Trial: 7635541
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous phenylephrine
Trial: 3530645
Drug: Intravenous nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroprusside
Trial: 7635541
Drug: Finapres measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finapres measurements during high-dose intravenous phenylephrine
Trial: 7635541
Drug: Finapres measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finapres measurements during intravenous nitroprusside
Trial: 7635541
Drug: Regional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional infusion of phenylephrine
Trial: 7635541
Drug: Regional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional infusion of nitroprusside
Trial: 31845837
Drug: Extragonadal steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extragonadal steroids
Trial: 31845837
Drug: Total androgen
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total androgen receptor transcriptional activity secondary to testosterone, dihydrotestosterone, and androstenedione
Trial: 24328444
Drug: Control (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hepatitis A vaccine)
Trial: 25697247
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline enemas with glycerol (0.8 ml glycerol + 3 ml saline or 1 ml glycerol + 5 ml saline)
Trial: 22806274
Drug: Abatacept (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (two different dose regimens)
Trial: 20236380
Drug: Q-switched YAG
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched YAG laser treatment (Q-YAG 5 system, 1064 nm, Palomar Inc., Burlington, VT, USA); series of three treatments at 6-week intervals.
Trial: 20236380
Drug: Punch biopsy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Punch biopsy excision; one treatment.
Trial: 12088160
Drug: Nefazodone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (mean final dose = 466 mg/day)
Trial: 12088160
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nefazodone (mean dose = 460 mg/day) and CBASP (mean = 16.2 sessions)
Trial: 9827437
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of baclofen (initially 156 μg/24 hours, increased to 280 μg/24 hours)
Trial: 2559484
Drug: Fragmin (2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin (2,500 anti Xa units, subcutaneously, once daily for 5-9 days)
Trial: 2559484
Drug: Placebo (subcutaneously,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneously, once daily for 5-9 days)
Trial: 206990
Drug: Normal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal treatment program
Trial: 31429811
Drug: ondansetron (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (titrated up to 24 mg daily)
Trial: 28214385
Drug: HIGH (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH (6 doses of 250 IU/kg over two weeks)
Trial: 28214385
Drug: COMB (HIGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMB (HIGH dose plus nine micro-doses over three weeks)
Trial: 22136019
Drug: Blood-pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-pricking therapy combined with rehabilitation
Trial: 22136019
Drug: Blood-pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-pricking therapy
Trial: 19592054
Drug: L-arginine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6.4 g/d) for 6 months
Trial: 17460405
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment applied twice daily for 3 weeks
Trial: 17460405
Drug: 0.12% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% betamethasone valerate ointment applied twice daily for 3 weeks
Trial: 15544076
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue combined with fibrinolysis inhibitor (aprotinin)
Trial: 11913478
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg three times daily for 2 months)
Trial: 9152114
Drug: Vecuronium bromide
RxNorm normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium bromide (0.15 mg/kg)
Trial: 9152114
Drug: Pancuronium bromide
RxNorm normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pancuronium bromide (0.1 mg/kg)
Trial: 9152114
Drug: Saline (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.15 mL/kg)
Trial: 7959156
Drug: sulbactam/ampicillin 0.5/1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulbactam/ampicillin 0.5/1.0 g, i.v. administered during surgery and repeated 6 hours later
Trial: 26571184
Drug: Albumin and
RxNorm normalized name: Bovine serum albumin and glutaraldehyde only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin and crystalloid solutions
Trial: 29481425
Drug: Crystalloid solutions
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid solutions alone
Trial: 25646891
Drug: 17 of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 of the 20 medications
Trial: 20090562
Drug: Enzastaurin plus
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin plus pemetrexed (250 mg two times per day; 500 mg/m intravenously on day 1 of 21-day cycles)
Trial: 20090562
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m intravenously on day 1 of 21-day cycles)
Trial: 20090562
Drug: Enzastaurin plus
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin plus pemetrexed (combination arm)
Trial: 18381986
Drug: Random drug
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random drug testing conducted in school districts
Trial: 18381986
Drug: Random drug
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random drug testing for athletes
Trial: 18381986
Drug: Random drug
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random drug testing for students in extracurricular activities
Trial: 18381986
Drug: Random drug
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random drug testing for all students
Trial: 15538040
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toremifene (TOR) 40 mg for 1 year
Trial: 15538040
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg for 1 year
Trial: 11006188
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase
Trial: 11006188
Drug: No GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GnRH agonist or antagonist
Trial: 8315554
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg p.o. (oral administration)
Trial: 8315554
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg i.m. (intramuscular administration)
Trial: 18487998
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived mononuclear cell therapy
Trial: 14686230
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1 g three times daily
Trial: 31295205
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment program combined with office-based canalith repositioning procedure (CRP)
Trial: 31295205
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Home treatment + CRP and CRP only)
Trial: 26841526
Drug: Comprehensive spa
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive spa and health resort-based treatment with manual therapy
Trial: 26841526
Drug: Balneotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapeutic treatment without manual therapy
Trial: 25885729
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg crystalloid infusion (Group I)
Trial: 25885729
Drug: 30 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml/kg crystalloid infusion (Group II)
Trial: 17091128
Drug: Naltrexone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (12 mg) + THC (20 mg)
Trial: 17091128
Drug: Naltrexone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (12 mg) + THC (40 mg)
Trial: 17091128
Drug: Naltrexone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (12 mg) + THC (2.5 mg)
Trial: 17091128
Drug: Naltrexone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (12 mg) + THC (10 mg)
Trial: 11485281
Drug: Atropa belladonna
RxNorm normalized name: ATROPA BELLADONNA
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropa belladonna tincture (ABT) 5 ml
Trial: 11485281
Drug: Atropa belladonna
RxNorm normalized name: ATROPA BELLADONNA
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropa belladonna tincture (ABT) 1 ml
Trial: 11485281
Drug: Atropa belladonna
RxNorm normalized name: ATROPA BELLADONNA
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropa belladonna tincture (ABT) 2 ml
Trial: 9771953
Drug: Cisplatin at
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at a dose of 80 mg/m2 on day 1 and etoposide at a dose of 100 mg/m2 on days 1, 2 and 3
Trial: 25134034
Drug: Brief alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief alcohol use disorder treatments
Trial: 17714844
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg D‐amphetamine alone
Trial: 17714844
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg riluzole alone
Trial: 15010405
Drug: 3.5% urea-linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5% urea-linked gelatin (GEL group)
Trial: 8449579
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 125 mg twice daily for three days
Trial: 8449579
Drug: Ofloxacin 100
RxNorm normalized name: ofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 100 mg twice daily for three days
Trial: 31967673
Drug: Bevacizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (8 mg/kg) and Everolimus (4 mg/m2)
Trial: 31967673
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg) and Everolimus (4 mg/m2)
Trial: 25842470
Drug: Cosmetic topical
RxNorm normalized name: Cosmetic Topical application Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmetic topical slimming treatment
Trial: 23976883
Drug: Sodium dichloroisocyanurate
RxNorm normalized name: Sodium dichloroisocyanurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium dichloroisocyanurate (NaDCC) tablets distributed during bi-monthly household visits; intervention included an intensive promotion campaign.
Trial: 23976883
Drug: Sodium dichloroisocyanurate
RxNorm normalized name: Sodium dichloroisocyanurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium dichloroisocyanurate (NaDCC) tablets intervention.
Trial: 19011582
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) treatment for 1 hour once a day for 20 days over 4 weeks
Trial: 19011582
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy treatment (CPT) protocol for 1 hour once a day for 20 days over 4 weeks
Trial: 11747981
Drug: Metyrapone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (1 g orally daily for 14 days)
Trial: 31394939
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) for 12 weeks
Trial: 31394939
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) during exercise
Trial: 31394939
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension (n=11)
Trial: 31394939
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension
Trial: 25308211
Drug: Theracurmin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theracurmin (180 mg/day)
Trial: 20383874
Drug: High-dose NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose NAC (1200 mg) plus saline hydration (Group 1, n=25)
Trial: 18757783
Drug: Odiparcil with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odiparcil with aspirin (ASA)
Trial: 11916799
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% with fentanyl 2 microg/mL at 10 mL/h
Trial: 11916799
Drug: Bupivacaine 0.0625%
RxNorm normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.0625% with fentanyl 2 microg/mL at 10 mL/h
Trial: 11916799
Drug: Bupivacaine 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.04% with epinephrine 1:600,000 and fentanyl 2 microg/mL at 10 mL/h
Trial: 9583771
Drug: Amantadine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (200 mg)
Trial: 8559197
Drug: eberconazole cream
RxNorm normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eberconazole cream 1% once daily (group A)
Trial: 8559197
Drug: eberconazole cream
RxNorm normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eberconazole cream 1% twice daily (group B)
Trial: 8559197
Drug: eberconazole cream
RxNorm normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eberconazole cream 2% once daily (group C)
Trial: 8559197
Drug: eberconazole cream
RxNorm normalized name: Terconazole
DrugBank: Eberconazole (DB13656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eberconazole cream 2% twice daily (group D)
Trial: 28301292
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PWM red LED light treatment)
Trial: 23579103
Drug: Ropivacaine 7.5mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7.5mg/mL
Trial: 21994354
Drug: ACE527 (three-strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE527 (three-strain combination live attenuated vaccine) at doses of 10^10 and 10^11 total CFU
Trial: 19523014
Drug: i.v. omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. omeprazole (OME group, 40 mg i.v. infusion every 12 h for 3 days)
Trial: 19523014
Drug: oral rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral rabeprazole (RAB group, 20 mg twice daily for 3 days)
Trial: 19523014
Drug: oral rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral rabeprazole (RAB group)
Trial: 11688083
Drug: Level 1
RxNorm normalized name: PALFORZIA (Level 10) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 1 sugar (10 mg of iron/kg of sugar)
Trial: 11688083
Drug: Level 2
RxNorm normalized name: True Metrix Control Level 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 2 sugar (100 mg of iron/kg of sugar)
Trial: 9716763
Drug: Five weekly
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five weekly practice sessions (Group A)
Trial: 2605074
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (control group)
Trial: 4394650
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol administration
Trial: 4394650
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol administration
Trial: 31034700
Drug: Patient-related factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class)
Trial: 31034700
Drug: Using cholinergic
RxNorm normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using cholinergic classes of medications
Trial: 25618418
Drug: Wholegrain diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wholegrain diet (>80 g/day)
Trial: 25618418
Drug: Refined grain
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined grain diet (<16 g/day)
Trial: 22176653
Drug: High-dose ascorbic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ascorbic acid (vitamin C) for 4 weeks
Trial: 17071939
Drug: Topotecan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.75 mg/m2, days 1-5, and carboplatin AUC 5, day 5 (arm A)
Trial: 17071939
Drug: Topotecan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.25 mg/m2, days 1-3, and carboplatin AUC 5, day 3 (arm B)
Trial: 16291354
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and zinc supplementation (30 mg ferrous fumarate, 30 mg zinc oxide, both, or placebo daily for 6 months)
Trial: 6862582
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) in hyperadrenergic patients
Trial: 31082512
Drug: Standardised Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised Chinese herbal medicine (CHM)
Trial: 31082512
Drug: Individualised Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised Chinese herbal medicine (CHM)
Trial: 24759256
Drug: Grains of
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grains of paradise (GP) extract (30 mg/d) for 4 weeks
Trial: 23038982
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of dried barberry (600 mg daily for 4 weeks)
Trial: 17984165
Drug: atorvastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin alone
Trial: 1961959
Drug: Thiopental, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental, 4 mg/kg